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Abstract
Purpose Although, drug–drug interactions (DDIs) between
potassium-increasing drugs (PIDs) are known risk factors for
developing hyperkalaemia, not much is known about their risk
and management strategies during hospitalisation. This study
examines the frequency of serum potassium measurements
and hyperkalaemia in hospitalised patients, based on the use
of one or more PIDs, and the determinants thereof.
Methods Adult patients hospitalised in the University
Medical Centre Utrecht between 2006 and 2008 were
included in this cross-sectional study. The frequency of serum
potassium measurements and of hyperkalaemia were
compared between patients using only one PID at a time
(monotherapy group) and patients using two or more PIDs
concomitantly (interaction group). The determinants studied
were renal failure, diabetes mellitus, use of diuretics, type of
DDI, start of the PIDs within the hospital versus continued
home medication and medical speciality.
Results Serum potassium was measured more frequently in
the interaction group than in the monotherapy group [67 vs.
56%; relative risk (RR) 1.19, 95% confidence interval (CI)
1.14–1.24] and the risk of hyperkalaemia was also
increased in the interaction group (9.9 vs. 5.9%, RR 1.7,
95% CI 1.3–2.1). The combination of potassium-sparing
diuretics plus a potassium supplement, start of the PID
within the hospital and hospitalisation in non-internal
medicine departments was associated with higher relative
risk estimates for hyperkalaemia.
Conclusions Among our patient cohort, even when physi-
cians received a direct pop-up to monitor serum potassium
levels when prescribing two PIDs concomitantly, serum
potassium levels were not measured in 33% of patients, and
10% of patients developed hyperkalaemia. Improved
management strategies and/or clinical decision-support
systems are needed to decrease the frequency of hyper-
kalaemia following DDIs.
Keywords Potassium . Hyperkalaemia . Drug–drug
interactions .Monitoring . Clinical risk management .
Clinical decision support
Introduction
Drug–drug interactions (DDIs) often lead to preventable
adverse drug events and contribute to the burden of drug-
related health damage [1, 2]. The interaction between serum
potassium concentration-increasing drugs (PIDs) is one of
the most frequently occurring DDI and has been reported to
occur in 8–10% of all hospitalised and non-hospitalised
patients [3, 4].
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Hyperkalaemia is a serious and potentially life-threatening
electrolyte disorder that follows from an imbalance in
potassium homeostasis [5]. The magnitude of the risk of
hyperkalaemia caused by the combined use of two or more
PIDs was highlighted after the findings of the Randomized
Aldactone Evaluation Study (RALES) were implemented in
regular patient care. In 1999, the RALES demonstrated
significantly improved outcomes for congestive heart failure
patients treated with spironolactone in combination with
diuretics and angiotensin-converting enzyme (ACE)-
inhibitors [6]. Five years later, in 2004, it was found that
this publication had resulted in a clear increase in the
prescription rates for spironolactone as well as a marked
increase in hyperkalaemia-associated morbidity and mor-
tality [7]. The risk does not only exist for renin–
angiotensin system (RAS) inhibitors and spironolactone,
but also for other combinations of PIDs, including
potassium supplements [8–11].
Many studies have investigated the risk of developing
hyperkalaemia from DDIs between PID’s, but most studies
have been performed in an outpatient setting, upon hospital
admission, in a specific patient group or with a specific
combination of PIDs. Moreover, in these studies, serum
potassium levels were often measured per protocol and
were closely monitored. No published data are available on
the risk and management strategies of combining PIDs
during hospitalisation when the average stay is only a few
days and access to laboratory measurement data is easier.
Therefore, the objective of this study is to examine the
frequency of serum potassium measurements and of hyper-
kalaemia for hospitalised patients using one or more PIDs,
and determinants there of.
Methods
Setting
This cross-sectional study was performed at the University
Medical Centre Utrecht (UMCU), a 1042-bed academic
medical centre located in the centre of the Netherlands.
Between 2006 and 2008, approximately 30,000 clinical
hospitalisations took place annually. All medications for
hospitalised patients are prescribed using a computerized
physician order entry (CPOE) system. In the Netherlands,
a working group of the Scientific Institute of Dutch
Pharmacists developed and maintains an evidence-based
and professional guideline for the management of DDIs,
called the G-standard, which is described in detail
elsewhere [12]. For clinical risk management purposes,
the G-standard is incorporated into the CPOE system [13].
All drugs in the G-standard are coded according to the
Anatomical Therapeutical Chemical Classification (ATC)
index. The ATC code system is an international standard
for drug utilisation studies determined by a World Health
Organisation (WHO) InternationalWorking Group [14]. Each
DDI in this guideline was assessed by four core parameters:
(1) evidence on the interaction; (2) clinical relevance of the
potential adverse reaction resulting from the interaction; (3)
risk factors identifying patient, medication or disease
characteristics for which the interaction is of special
importance; (4) incidence of the adverse reaction. Based on
the information in the G-standard, the CPOE generates an
alert when a combination of two or more interacting drugs
are prescribed concomitantly. In the case the concomitant
prescribing of two PIDs, the physician receives a direct pop-
up that there is a risk of hyperkalaemia and that the serum
potassium levels should be closely monitored.
For research purposes all prescriptions are routinely
exported into the Utrecht Patient Oriented Database
(UPOD), which is an infrastructure of relational data-
bases comprising data on patient demographics, hospital
discharge diagnoses, medical procedures, medication
orders and laboratory tests for all patients treated at the
UMCU since 2004. This database is described in detail
elsewhere [15].
Study population
All patients aged >18 years who were hospitalised in the
UMCU between 2006 and 2008 for ≥24 h and who were
prescribed at least one PID were enrolled in the study. If a
patient was admitted during the study period to the hospital
more than once, only the first admission was included.
Patients admitted to the dialysis department were excluded
because patients with end-stage renal disease lack the renal
compensation mechanism for potassium homeostasis and
large variations in serum potassium levels may occur due to
dialysis. Patients admitted to the intensive care (IC) units
were also excluded because a different CPOE system is
used in the IC units and the prescription data are not (yet)
stored in the UPOD database.
Exposure
Patients who were prescribed one PID (monotherapy
group) were compared to patients who were prescribed
two or more PIDs concomitantly (interaction group). In this
study, PIDs were defined as: (1) RAS inhibitors, (2)
potassium-sparing diuretics or (3) potassium supplements.
The professional DDI clinical risk management guideline
has defined a combination of these drugs as a risk for
developing hyperkalaemia. Other combinations of poten-
tially PIDs mentioned in literature, such as nonsteroidal
anti-inflammatory drugs, β-adrenergic blocking drugs,
heparin and trimethoprim, are not considered to be
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sufficiently relevant by the professional DDI clinical risk
management guideline and were therefore not included.
Outcome
Two different outcome measures were studied: (1) frequency
of serum potassium measurements and (2) frequency of
hyperkalaemia. The frequency of serum potassium measure-
ments was defined as the percentage of patients for which a
serum potassium level was measured at least once during the
hospitalisation period. The frequency of hyperkalaemia was
defined as the percentage of patients with any serum
potassium measurement ≥5.5 mEq/L during the hospital-
isation period.
Determinants
In addition to age and gender, the following determinants
were studied:
– Renal function: glomerular filtration rates were estimated
(eGFR) using the Modification of Diet in Renal Disease
(MDRD) equation [16, 17] using the highest serum
creatinine level measured during the hospitalisation
period. A decreased renal function is a known risk
factor for hyperkalaemia.
– Diabetes mellitus: a patient was considered to have
diabetes mellitus when one or more medication orders
for any anti-diabetic medication had been prescribed
during hospitalisation. Anti-diabetic medication was
defined as medication with ATC code “A10”. Diabetes
mellitus is also a known risk factor for hyperkalaemia.
– Diuretics: any use of diuretics. This was defined as the
use of lis- or thiazide diuretica or a combination of
drugs containing thiazide diuretics during hospitalisation
(ATC C03C, C03A). This determinant was studied
because both the use of thiazide- and lisdiuretics have
been associated with a protective effect against the
development of hyperkalaemia [18]
– Type of combination: in the interaction group three
combinations are possible, namely (1) RAS-inhibitor +
potassium-sparing diuretic, (2) RAS-inhibitor + potassium
supplement, (3) potassium sparing diuretic + potassium
supplement.
– Start at home or start during hospitalisation: in the
monotherapy group, start at home was defined as the
first PID prescribed in the CPOE system within 24
h of arrival in the hospital. In the interaction group.
start at home was defined as the second PID
prescribed in the CPOE system within 24 h of arrival
in the hospital. PIDs prescribed >24 h after admis-
sion were considered to be newly started within the
hospital.
– Department: internal medicine departments versus non-
internal medicine departments. Internal medicine depart-
ments were defined as general internal medicine depart-
ments (namely. Heart & Lung departments and the
departments of Geriatrics, Nephrology and Oncology).
Non-internal medicine departments were mainly
the Surgery, Neurology, Psychiatry and Gynaecology
departments.
Data analysis
Relative risks (RR) with corresponding 95% confidence
intervals (CI) were calculated for both outcome measures.
The SPSS Package for Social Sciences software (SPSS) ver.
15.1 for Windows (SPSS, Chicago, IL) was used to analyse
the collected data.
Results
A total of 9,441 patients using at least one PID were included
in this study of whom 1,396 (14.7%) used two or more
PIDs concomitantly at a time during their hospitalisation
(interaction group). On average, patients using ≥2 PIDs were
older, had a worse kidney function and used anti-diabetic
drugs and diuretics more often than patients using only one
PID (monotherapy group) (Table 1). Of the patients in the
monotherapy group, 35% started PID therapy during their
stay in the hospital; of those using ≥2 PIDs, 50.4% were first
prescribed the second PID during their hospital stay.
Serum potassium was measured more frequently in the
interaction group than in the monotherapy group (67 vs.
56%, respecively, RR 1.19, 95% CI 1.14–1.24), and the risk
of hyperkalaemia was also higher in the interaction group
(9.9 vs. 5.9%, respectively, RR 1.7, 95% CI 1.3–2.1)
(Table 2). For patients whose potassium was measured at
least once, a median of 0.67 measurements per hospital
admission day were performed in the interaction group and
0.50 in the monotherapy group.
There were no differences in the relative risk estimates
between the monotherapy and interaction groups when age,
gender, renal function, diabetes and use of diuretics were
stratified. The absolute risk of hyperkalaemia, however,
was higher in patients with an eGFR≤50 mL/min (p<0.01
for both monotherapy and interaction groups).
Comparison of the risk of hyperkalaemia for the different
interaction types revealed that the risk was higher for the
combination of a potassium supplement plus a potassium-
sparing diuretic (RR 3.0, 95% CI 2.0–4.4) than for the two
other combinations: a potassium-sparing diuretic plus RAS-
inhibitor (RR 1.5, 95% CI 1.1-2.1) and a potassium
supplement plus RAS-inhibitor (RR 1.3, 95% CI 0.9–2.0).
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The relative risk estimate was also found to be higher
when the PIDs were first prescribed during hospitalisation
(RR 2.14, 95% CI 1.60–2.88) than when they were already
started at home (RR 1.13, 95% CI 0.77–1.66). Serum
potassium levels were measured more frequently when
PIDs were started during hospitalisation in both the
interaction (63.0 vs. 70.2%, p<0.01) and the monotherapy
group (52.1 vs. 63.6%, p<0.01).
When stratifying for type of department, the relative
risk estimate for developing hyperkalaemia was found to
be higher for patients hospitalised in non-internal
medicine departments (RR 2.7, 95% CI 1.7–4.3) than
in those hospitalised in internal medicine departments
(RR 1.3, 95% CI 1.0–1.6). Serum potassium measure-
ments were made more frequently for patients of both
groups hospitalised in internal medicine departments than
in non-internal medicine departments (monotherapy: 66.4
vs. 47.5%, p<0.01; interaction groups: 68.6 vs. 62.1%,
p=0.018).
Discussion
In the patients of our hospital who participated in this study,
serum potassium levels were measured in only 56–67% of
patients using one or more PIDs. Hyperkalaemia, defined as
a serum potassium concentration ≥5.5 mEq/L, occurred in
6–10% of patients. The absolute risk for developing
hyperkalaemia was highest for patients with a eGFR≤50
and for patients with diabetes mellitus. However, the
relative risk estimates for comparing interaction to mono-
therapy were not increased for age, gender, kidney function
and diabetes. When using two or more PID’s concomitantly,
the risk of hyperkalaemia was elevated in patients using a
combination of a potassium-sparing diuretic with a potassium
supplement, in patients starting their PID therapy during their
hospitalisation period and in patients hospitalised in non-
internal medicine departments.
Serum potassium measurements were made more fre-
quently for patients in the interaction group than for those
Table 1 Baseline characteristics for monotherapy group (users of 1 PID) versus interaction group (users of ≥2 PIDs)
Baseline characteristics Monotherapy: 1 PID (n=8,045) Interaction: ≥2 PIDs (n=1,396) p valuea
Median length of stay, days (interquartile range) 6.18 (3.0-12.0) 8.9 (4.2-16.1) <0.001
Mean age, years (95% CI) 62.2 (61.8-62.5) 67.3 (66.6-68.1) <0.001
Male gender 3,981 (49.5%) 751 (53.8%) <0.01
Renal function <0.001
eGFR≥80 mL/min 1,479 (18.4%) 123 (8.8%)
eGFR 50–80 mL/min 1,876 (23.3%) 375 (26.9%)
eGFR≤50 mL/min 1,150 (14.3%) 422 (30.2%)
Unknown 3,540 (44.0%) 476 (34.1%)
Diabetes mellitus 1,582 (19.7%) 340 (24.4%) <0.001
Diuretics 3,106 (38.6%) 1,097 (78.6%) <0.001
Drug type (first monotherapy) n.a.
RAS inhibitor 4,819 (59.9%)
Potassium sparing diuretic 622 (7.7%)
Potassium supplement 2,604 (32.4%)
Interaction type n.a.
RAS-inhibitor + potassium sparing diuretic 707 (50.6%)
RAS-inhibitor + potassium supplement 501 (35.9%)
Potassium sparing diuretic + potassium supplement 188 (13.5%)
Start drug/interaction <0.001
At home 5,192 (64.5%) 692 (49.6%)
During hospitalisation 2,853 (35.5%) 704 (50.4%)
Department <0.001
Internal medicine specialities 3,694 (45.9%) 977 (70.0%)
Non-internal medical specialities 4,351 (54.1%) 419 (30.0%)
Data are given as the number (n) of patients, with the percentage in parenthesis, unless indicated otherwise
PID, Potassium-increasing drug; CI, confidence interval; eGFR, estimated glomerular filtration rate; RAS, renin–angiotensin system, n.a., not
applicable
a Chi-square test (categorical variables) or t test (continuous variables) as appropriate
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in the monotherapy group. This may suggest that the
interaction alerts, namely, direct pop-ups advising physi-
cians to monitor potassium levels, were indeed (partly)
effective. However, the higher frequency may also be due
to the longer hospital stay of patients in the interaction
group and differences in patients characteristics between the
interaction group and monotherapy group. To check our
assumption that the higher frequency of serum potassium
measurements in the interaction group was indeed caused
by a drug interaction signal, we compared the interaction
and the monotherapy groups for the measurement of two
‘neutral markers’, that is leukocyte count and haemoglobin
level. We found that both markers were measured more
frequently in the interaction group than in the monotherapy
group (66 vs. 58%, p<0.01 for haemoglobin level, and 63
vs. 51%, p<0.01 for leukocyte count, respectively; results
not shown). This result indicates that the higher frequency
of potassium measurements in the interaction group may
not be (entirely) due to warnings about the drug-drug
interaction, but may also be explained by differences in
patient characteristics between patients using only one PID
and patients using ≥2 PIDs. Apparently, more laboratory
measurements were required in the interaction group, which
may suggest that these patients were more severely ill or
that they had more complex diseases or more co-morbidity.
As shown in Table 2, serum creatinine and serum
potassium were always almost measured simultaneously.
When renal function was known, serum potassium was
Table 2 Percentage of patients in whom serum potassium was measured and percentage of patients with hyperkalaemia (defined as serum














Overall 56.2% (4,520/8,045) 66.6% (930/1,396) 1.19 (1.14-1.24) 5.9% (267/4,520) 9.9% (92/930) 1.68 (1.34-2.10)
Age (years)
18–50 56.8% (989/1,742) 70.8% (114/161) 1.25 (1.12-1.39) 6.2% (61/989) 12.3% (14/114) 1.99 (1.15-3.44)
50–70 55.3% (1,921/3,473) 64.3% (369/574) 1.16 (1.09-1.24) 5.6% (107/1,921) 8.4% (31/369) 1.51 (1.03-2.21)
70–80 54.7% (964/1,761) 68.5% (263/384) 1.25 (1.16-1.36) 5.2% (50/964) 9.5% (25/263) 1.83 (1.16-2.90)
≥80 60.4% (646/1,069) 66.4% (184/277) 1.10 (1.0-1.21) 7.6% (49/646) 12.0% (22/184) 1.58 (0.98-2.54)
Gender
Male 58.4% (2,326/3,981)) 67.4% (506/751) 1.15 (1.09-1.22) 6.3% (147/2,326) 9.5% (48/506) 1.50 (1.10-2.05)
Female 54.0% (2,194/4,064) 65.7% (424/645) 1.22 (1.14-1.30) 5.5% (120/2,194) 10.4% (44/424) 1.90 (1.37-2.64)
Renal function
eGFR≥80 mL/min 97.2% (1,438/1,479) 99.2% (122/123) 1.02 (1.00-1.04) 2.5% (36/1,438) 4.1% (5/122) 1.64 (0.65-4.10)
eGFR 50–80 mL/min 97.5% (1,829/1,876) 99.7% (374/375) 1.02 (1.01-1.03) 2.6% (48/1,829) 4.0% (15/374) 1.53 (0.87-2.70)
eGFR≤50 mL/min 99.3% (1,142/1,150) 99.8% (421/422) 1.01 (1.00-1.01) 15.8% (181/1,142) 16.9% (71/421) 1.06 (0.83-1.37)
Unknown 3.1% (111/3,540) 2.7% (13/476) 0.87 (0.49-1.54) 1.8% (2/111) 7.7% (1/13) 4.27 (0.42-43.91)
Diabetes 54.0% (855/1,582) 69.1% (235/340) 1.28 (1.18-1.39) 10.1% (86/855) 12.8% (30/235) 1.27 (0.86-1.87)
Non-diabetes 56.7% (3,665/6,463) 65.8% (695/1,056) 1.16 (1.11-1.22) 4.9% (181/3,665) 8.9% (62/695) 1.81 (1.37-2.38)
Diuretics 55.5% (1,723/3,106) 66.5% (730/1,097) 1.20 (1.14-1.26) 7.7% (133/1,723) 10.8% (79/730) 1.40 (1.08-1.83)
Thiazide 45.0% (597/1328) 63.4% (92/145) 1.41 (1.23-1.62) 1.5% (9/597) 4.3% (4/92) 2.88 (0.91-9.17)
Loop 62.9% (1,036/1,648) 67.3% (588/874) 1.07 (1.01-1.14) 10.5% (109/1036) 11.2% (66/588) 1.07 (0.80-1.42)
Thiazide + loop 69.2% (90/130) 64.1% (50/78) 0.93 (0.76-1.13) 16.7% (15/90) 18.0% (9/50) 1.08 (0.51-2.29)
No diuretics 56.6% (2,797/4,939) 66.9% (200/299) 1.18 (1.09-1.28) 4.8% (134/2,797) 6.5% (13/200) 1.36 (0.78-2.35)
Interactiona
Type1 56.2% (4,520/8,045) 65.6% (464/707) 1.17 (1.10-1.24) 5.9% (267/4,520) 9.1% (42/464) 1.53 (1.12-2.10)
Type 2 56.2% (4,520/8,045) 65.9% (330/501) 1.17 (1.10-1.25) 5.9% (267/4,520) 7.9% (26/330) 1.33 (0.91-1.96)
Type 3 56.2% (4,520/8,045) 72.3% (136/188) 1.29 (1.18-1.41) 5.9% (267/4,520) 17.6% (24/136) 2.99 (2.04-4.37)
Start drug or interaction
At home 52.1% (2,706/5,192) 63.0% (436/692) 1.21 (1.14-1.29) 5.9% (159/2,706) 6.7% (29/436) 1.13 (0.77-1.66)
During hospitalisation 63.6% (1,814/2,853) 70.2% (494/704) 1.10 (1.04-1.17) 6.0% (108/1,814) 12.8% (63/494) 2.14 (1.60-2.88)
Department
Internal medicine specialities 66.4% (2,453/3,694) 68.6% (670/977) 1.03 (0.98-1.08) 8.2% (202/2,453) 10.4% (70/670) 1.27 (0.98-1.64)
Non-internal medical specialities 47.5% (2,067/4,351) 62.1% (260/419) 1.31 (1.20-1.42) 3.1% (65/2,063) 8.5% (22/260) 2.69 (1.69-4.29)
a Type 1, RAS-inhibitor+potassium sparing diuretic; type 2, RAS-inhibitor+potassium supplement; type 3, potassium sparing diuretic+potassium
supplement
Eur J Clin Pharmacol (2011) 67:933–940 937
measured in 97–99% of patients, while if it was unknown,
serum potassium was measured in only about 3% of patients.
It is likely that the same holds true for the measurement of, for
example, sodium. As such, serum potassium measurements
may not always be carried out with the intention to monitor
potassium, but simply as an adjunct.
As expected, the frequency of hyperkalaemia was much
higher in patients with an estimated eGFR≤50 mL/min than
in patients with an estimated eGFR>50 mL/min. Patients
with chronic renal failure are known to be at risk of
developing hyperkalaemia [19]. It is also known that the
use of a PID may contribute to this risk in patients with
renal failure [20]. In our patient cohort, however, this risk
did not further increase for patients using ≥2 PIDs (15.8 vs.
16.9% for the monotherapy and interaction groups, respec-
tively). It is possible that monotherapy already requires the
maximum capacity of renal autoregulation. If so, this may
not leave much space for a further increase in risk when
≥2 PIDs are used concomitantly.
A comparable result was seen in diabetic patients: diabetes
is a known risk factor for hyperkalaemia [10, 19, 21]. In our
study however, the introduction of a second PID did not
increase the risk, suggesting that risk factors for developing
hyperkalaemia due to a DDI are not the same as those for
developing hyperkalaemia after a DDI.
The frequency of hyperkalaemia in patients using a
thiazide diuretic seemed to be lower than that in patients
without diuretics, which is suggestive for a protective effect
in both the monotherapy and interaction groups. This
protective effect was not seen for the use of loop diuretics
or for the combination of a thiazide and a loop diuretic in
the co-medication group. The use of diuretics is a known
protective factor for the development of hyperkalaemia
[18]. Weinberg reported a 59% reduction in the probability
of hyperkalaemia with the use of diuretics; however,
thiazide diuretics, not loop diuretics, were found to
contribute the most to this effect [10].
A comparison of the different combinations of PIDs
revealed that hospitalised patients using potassium-sparing
diuretics combined with potassium supplements had the
highest risk of hyperkalaemia. Of course, the risk of
hyperkalaemia is obvious for this combination, and some
authors have even argued that an alert is superfluous in this
situation [22]. Indermitte et al. found that the use of
potassium supplements contributed most strongly to the
velocity of developing hyperkalaemia [18], while others
found that the combination of PID with RAS-inhibitors was
the strongest predictor to develop hyperkalaemia in hospi-
talised patients [10].
Patients who were started on interacting PIDs during
hospitalisation were at a higher risk developing hyper-
kalaemia than patients who were started taking their
interacting PID therapy at home. One possible explanation
may be when the interacting medication was started at
home, prior to hospitalisation, serum potassium levels may
already have been monitored before the patient was
hospitalised. Adjustments may have been made, such as
by decreasing the dose of the PIDs or adding medicine to
the therapeutic regimen for decreasing the potassium serum
level [23]. It may also be possible that the PIDs caused only
a temporary rise of serum potassium levels. Moreover, one
might expect that physicians are more inclined to monitor
the effects of newly added medication than of continued
home-medication [24]. Indeed, the serum potassium levels
were measured somewhat more often in the group of
patients who started the PIDs in the hospital than in the
group of patients who continued their PID home-
medication. This was seen in both the monotherapy and
interaction group (63.6 vs. 52.1%, p<0.01 and 70.2 vs.
63.0%, p<0.01 respectively).
Finally, the relative risk estimate for developing hyper-
kalaemia was higher for patients hospitalised in non-
internal medicine departments (RR 2.7, 95% CI 1.7–4.3)
than in patients hospitalised in internal medicine depart-
ments (RR 1.3, 95% CI 1.0–1.6). The frequency of serum
potassium measurements was also increased for patients
with an interaction (47.5 vs. 62.1%, RR 1.3, 95% CI 1.2–
1.4), but the absolute frequency of serum potassium
measurements was remarkably low for patients with
monotherapy in the non-internal medicine departments.
This may once again suggest that warning signals were
followed. The frequency of the measurement of the two
neutral markers, however, were also different (54.2 vs.
40.2%, p<0.01 for leucocytes and 62.3 vs. 50.3%, p<0.01
for haemoglobin), which means that differences in patient
characteristics may have played a role as well. Moreover,
the frequency of serum potassium measurements in the
monotherapy group of the non-internal departments is
relatively low, which may reflect the fact that physicians
working in non-internal departments are less preoccupied
with serum electrolyte levels than their counterparts
working in internal medicine departments. As such, they
may be less aware of the risk for developing hyperkalaemia
when prescribing a PID. Therefore, special attention is
needed for patients using PIDs in non-internal medicine
departments.
There are a number of limitations to our study. First, one
potential limitation may be that nonsteroidal anti-
inflammatory drugs, β-adrenergic blocking drugs, heparin
and trimethoprim were not included in our definition of a
PID. The exclusion of these drugs was deliberate as they
increase serum potassium levels to a far lesser extent than
RAS-inhibitors, potassium-sparing diuretics and potassium
supplements. As such, the former are not included in the
G-standard as DDIs, and the CPOE does not generate a
pop-up to warn for hyperkalaemia. Second, the local
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hospital setting may limit the generalisability of the results.
Finally, as this is an observational study, patients were not
randomised to either the monotherapy or the interaction
group, and serum potassium levels were not measured per
protocol. The differences in baseline characteristics make it
very clear that the patients in the monotherapy and the
interaction group are not the same. In addition, serum
potassium levels were not measured systematically in all
patients, but were known for only 56–66% of patients,
meaning that there is a testing bias [25]. As such, this
study does not aim to answer the etiologic question about
the contribution of DDIs to the risk of developing
hyperkalaemia. The objective was to study the consequen-
ces of a frequently encountered DDI in daily hospital
practice and to gain insight in the determinants thereof.
Consequently, the adjusted relative risk estimates have
consciously been omitted from Table 2, and only uni-
variate analysis were performed. The message is not so
much that these DDIs cause hyperkalaemia but that, in
daily practice, patients in the interaction group deserve
extra attention and that serum potassium measurements
should be made more frequently.
At our hospital, when two PIDs are prescribed concomi-
tantly, physicians directly receive a pop-up that there is a risk
of hyperkalaemia and that the serum potassium levels should
be monitored closely. However, we found that this advice was
not followed in 33% of patients. One of the reasons for this
may be that the warnings are not always appropriate. The DDI
signal always appears when a DDI occurs, even if the serum
potassium level is actually low, which may cause alert fatigue
[26, 27]. Another reason may be that the alert to monitor
potassium serum levels only occurs when the medication is
started. There are no subsequent reminders, while in fact it
will take at least a few days before a rise in serum potassium
levels can actually be determined.
More advanced methods of clinical decision support
may be suitable to improve the management of this DDI
and to reduce the frequency of hyperkalaemia. For
example, it may be worthwhile to generate a reminder
every 3–4 days to monitor serum potassium for all
hospitalised patients using two or more PIDs. Another
possibility would be to link laboratory and medication
data and to generate a warning when serum potassium
levels increase above a certain limit for patients using
one or more PIDs.
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